Aspen Pharmacare Holdings Limited

JSE:APN Lagerbericht

Marktkapitalisierung: R86.9b

Aspen Pharmacare Holdings Management

Management Kriterienprüfungen 4/4

Aspen Pharmacare Holdings' CEO ist Stephen Saad , ernannt in Jan 2000, hat eine Amtszeit von 24.58 Jahren. Die jährliche Gesamtvergütung beträgt ZAR24.15M , bestehend aus 38% Gehalt und 62% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 12.84% der Aktien des Unternehmens, im Wert von ZAR13.36B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.4 Jahre bzw. 5.3 Jahre.

Wichtige Informationen

Stephen Saad

Geschäftsführender

R24.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts38.0%
Amtszeit als Geschäftsführer24.7yrs
Eigentum des Geschäftsführers12.8%
Durchschnittliche Amtszeit des Managements7.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.4yrs

Jüngste Management Updates

Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Dec 01
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Dec 02
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Recent updates

Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59

Sep 10
Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59

We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt

May 08
We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt

Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable

Mar 05
Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable

Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Dec 22
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Dec 01
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Mar 31
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case

Jan 11
With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case

These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well

Oct 22
These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well

We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease

Oct 06
We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease

Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Sep 21
Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially

Sep 08
Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially

Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26

Sep 07
Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26

Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today

Jun 15
Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today

Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly

Apr 02
Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting

Mar 16
With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting

An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued

Mar 02
An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued

Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?

Dec 23
Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?

Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Dec 02
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative

Oct 11
We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative

After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar

Sep 30
After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar

Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump

Sep 30
Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Stephen Saad im Vergleich zu den Einnahmen von Aspen Pharmacare Holdings verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

R4b

Mar 31 2024n/an/a

R5b

Dec 31 2023n/an/a

R5b

Sep 30 2023n/an/a

R5b

Jun 30 2023R24mR9m

R5b

Mar 31 2023n/an/a

R6b

Dec 31 2022n/an/a

R6b

Sep 30 2022n/an/a

R6b

Jun 30 2022R23mR9m

R6b

Mar 31 2022n/an/a

R6b

Dec 31 2021n/an/a

R6b

Sep 30 2021n/an/a

R5b

Jun 30 2021R24mR8m

R5b

Mar 31 2021n/an/a

R4b

Dec 31 2020n/an/a

R4b

Sep 30 2020n/an/a

R4b

Jun 30 2020R23mR8m

R3b

Mar 31 2020n/an/a

R3b

Dec 31 2019n/an/a

R870m

Sep 30 2019n/an/a

R1b

Jun 30 2019R14mR8m

R2b

Mar 31 2019n/an/a

R3b

Dec 31 2018n/an/a

R5b

Sep 30 2018n/an/a

R5b

Jun 30 2018R17mR7m

R6b

Vergütung im Vergleich zum Markt: StephenDie Gesamtvergütung ($USD1.35M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt ZA ($USD1.72M).

Entschädigung vs. Einkommen: StephenDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Stephen Saad (60 yo)

24.7yrs

Amtszeit

R24,149,000

Vergütung

Mr. Stephen Bradley Saad, BCom, CA(SA), serves as the Group Chief Executive Officer of Aspen Pharmacare Canada Inc. Mr. Stephen has been the Group Chief Executive Officer of Aspen Pharmacare Holdings Limit...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Stephen Saad
Group CEO & Executive Director24.7yrsR24.15m12.84%
ZAR 11.2b
Sean Capazorio
Group CFO & Executive Director25.7yrsR15.55mkeine Daten
Lorraine Hill
Group Chief Operations Officer & Responsible Pharmacist10.8yrsR16.59mkeine Daten
Michael Attridge
Group Chief Advisor2.7yrsR12.62m4.31%
ZAR 3.7b
Reginald Haman
Group Chief Corporate Services Officer & Executive Directorless than a yearR14.21mkeine Daten
Zizipho Mmango
Group Chief Strategic Development Officer4.3yrsR13.87mkeine Daten
Sibongakonke Nkosi
Investor Relations Managerno datakeine Datenkeine Daten
Trevor Ziman
Regional Chief Executive Officer of Asia Pacific10.7yrskeine Datenkeine Daten
Samer Kassem
Chief Executive Officer of Aspen Global Incorporated7.5yrskeine Datenkeine Daten
Raeesa Khan
Group Company Secretaryless than a yearkeine Datenkeine Daten
Luresha Chetty
Corporate Affairs & Investor Relations Executiveno datakeine Datenkeine Daten

7.5yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: APNDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.4 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Stephen Saad
Group CEO & Executive Director25.7yrsR24.15m12.84%
ZAR 11.2b
Sean Capazorio
Group CFO & Executive Director2.7yrsR15.55mkeine Daten
Reginald Haman
Group Chief Corporate Services Officer & Executive Directorless than a yearR14.21mkeine Daten
Ben Kruger
Lead Independent Non-Executive Director5.4yrsR932.00kkeine Daten
Christopher Mortimer
Non-Executive Director25.7yrsR465.00kkeine Daten
Kuseni Dlamini
Independent Non-Executive Chairman12.4yrsR1.41mkeine Daten
Yvonne Muthien
Independent Non-Executive Director2.8yrsR548.00kkeine Daten
David Redfern
Non-Executive Director9.6yrsR364.00kkeine Daten
Linda de Beer
Independent Non-Executive Director6.2yrsR958.00kkeine Daten
Neo Dongwana
Independent Non-Executive Directorless than a yearkeine Datenkeine Daten
Themba Mkhwanazi
Independent Non-Executive Director5.4yrsR448.00kkeine Daten

5.4yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrener Vorstand: APNDie Vorstandsmitglieder gelten als erfahren (5.3 Jahre durchschnittliche Amtszeit).